AI Article Synopsis
Article Abstract
Summary: We present software to characterize and rank potential therapeutic (drug) targets with data from public databases and present it in a user-friendly format. By understanding potential obstacles to drug development through the gathering and understanding of this information, combined with robust approaches to target validation to generate therapeutic hypotheses, this approach may provide high quality targets, leading the process of drug development to become more efficient and cost-effective.
Availability And Implementation: The information we gather on potential targets concerns small-molecule druggability (ligandability), suitability for large-molecule approaches (e.g. antibodies) or new modalities (e.g. antisense oligonucleotides, siRNA or PROTAC), feasibility (availability of resources such as assays and biological knowledge) and potential safety risks (adverse tissue-wise expression, deleterious phenotypes). This information can be termed 'tractability'. We provide visualization tools to understand its components. TractaViewer is available from https://github.com/NeilPearson-Lilly/TractaViewer.
Supplementary Information: Supplementary data are available at Bioinformatics online.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/bioinformatics/btz270 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The evolving tumor-associated adipose tissue microenvironment in breast cancer: from cancer initiation to metastatic outgrowth.
Clin Transl Oncol
December 2024
Central Laboratory, The Affiliated Hospital of Yanbian University, Yanji, 133000, China.
Adipocytes represent a significant proportion of breast tissue, comprising between 3.7 and 37% of stromal tissue. They play a pivotal role in metabolic regulation, energy supply, metabolic regulation, support effects, and cytokine release within the breast.
View Article and Find Full Text PDFCuminaldehyde Potentiates Antiproteolytic Peptide Efficacy via Parallel Pathways of Enhanced Inner Membrane-Damaging Activity and Inhibition of Bacterial Energy Metabolism.
J Med Chem
December 2024
College of Animal Science and Technology, Northeast Agricultural University, Harbin 150030, P. R. China.
Antimicrobial peptides (AMPs) offer potential as antibiotic alternatives, but high cost, off-site cytotoxicity, and poor stability limit their application. Combining AMPs with adjuvants holds promise in surmounting these limitations. Among potentiators, terpenoids account for the highest proportion, yet their potential to enhance the AMPs efficacy and underlying mechanism remain unclear.
View Article and Find Full Text PDFSETDB1: an emerging target for anticancer drug development.
Future Med Chem
December 2024
Laboratório de Integração entre Técnicas Experimentais e (LITEC), Computacionais no Planejamento de Fármacos, Department of Pharmacy, School of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil.
Research progress and application status of organoid in breast cancer subtypes.
Biomol Biomed
December 2024
Department of Laboratory Medicine, The Affiliated Hospital of Southwest Medical University, Sichuan Province Engineering Technology Research Center of Molecular Diagnosis of Clinical Diseases, Molecular Diagnosis of Clinical Diseases Key Laboratory of Luzhou, Sichuan, China.
Breast cancer (BC) is a prevalent malignant tumor that poses a significant health risk to women. The complexity of basic BC research and clinical treatment is influenced by multiple factors, including age, fertility, hormone metabolism, molecular subtypes, and tumor grading and staging. Traditional in vitro models often fall short of meeting modern research demands, whereas organoids-an emerging 3D primary culture technology-offer a unique platform that better replicates the tumor microenvironment (TME).
View Article and Find Full Text PDFSwitch-Type Electrochemiluminescence Aptasensor for AFB1 Detection Based on CoS Quantum Dots Encapsulated in Co-LDH and a Ferrocene Quencher.
Anal Chem
December 2024
Guangdong Provincial Key Laboratory of Pharmaceutical Bioactive Substances, Center for Drug Research and Development, Guangdong Pharmaceutical University, Guangzhou, Guangdong 510006, China.
Among the various aflatoxin B1 (AFB1) assays, performing accurate detection is difficult because false positives and false negatives are frequent due to limited sensitivity, expensive equipment, or inadequate pretreatment during operation. Here, an "off-on" switch-type electrochemiluminescence (ECL) aptasensor armed with cobalt-sulfur quantum dots was encapsulated in hollow cobalt-layered double hydroxide nanocages as an enhanced luminescent probe (Co-LDH@QDs), and a ferrocene-modified aptamer (Fc-APT) was used as a luminescent quencher. In general, when Fc-APT was hybridized with complementary DNA modified with a DNA nanotetrahedron, electron transfer between ferrocene and Co-LDH@QDs was facilitated, leading to efficient quenching of the ECL intensity into an "off" state in the absence of AFB1.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!